Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach

Overview of attention for article published in Research and Reports in Endocrine Disorders, December 2012

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (77th percentile)

Mentioned by

blogs: 1 blog

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 3 Mendeley

Summary Blogs Dimensions citations

So far, Altmetric has seen 1 blog post.

Pituitary Neuroendocrine Axis

Pharmaceutical Intelligence, 04 Feb 2015

Larry H. Bernstein, MD, FCAP, Writer and Curator Pituitary Neuroendocrine Axis http://pharmaceuticalintelligence.com/2015/02/04/P…